89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
September 14, 2020 07:01 ET
|
89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
89bio Announces Proposed Public Offering of Common Stock
July 06, 2020 06:30 ET
|
89bio, Inc.
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
April 13, 2020 08:30 ET
|
89bio, Inc.
- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in...
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
March 25, 2020 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 18, 2020 16:05 ET
|
89bio, Inc.
- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:...
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
February 21, 2020 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...